eff Roberson/AP; Toby Melville / Reuters; Stefan Zaklin / Getty; Merck; Yutong Yuan/Business Insider
- Healthcare CEOs are some of the most well-paid executives in the US.
- We took a look at the compensation packages of the leaders overseeing some of the biggest healthcare companies.
- Here’s how much they took home in 2018, according to regulatory filings.
- Visit Business Insider’s homepage for more stories.
Leading a top healthcare company is a demanding job — and one for which CEOs are handsomely compensated.
There’s a lot that can come with the job title, from overseeing tens of billions of dollars in market value to testifying in front of Congress and finding ways to serve both shareholders and patients.
We took a look at the compensation packages of some of the leaders overseeing the largest healthcare companies. Included in packages were salaries, stock, and benefits like retirement and other incentives.
The pay packages range from single-digit millions to north of $26 million. Here’s how they stack up.
Allergan CEO Brent Saunders, $6,624,473
Reuters
Brent Saunders has been presiding over Allergan and its billion-dollar Botox empire since 2014, when a $66 billion merger launched the company as a member of Big Pharma.
Lately, though, Saunders’ tenure has hit rocky times. Allergan still turns out a profitable business in cosmetics and eye care, but competition is also shaping up in those areas.
David Tepper’s Appaloosa LP hedge fund has slammed Allergan’s recent track record, calling for an independent board chair at the company — a move seen as an implicit critique of Saunders. Allergan’s stock price was among Appaloosa’s criticisms: It has steadily trended down since mid-2015, losing roughly 50% of its value.
Saunders’ leadership also came under attack in 2017, when he spearheaded an ill-advised gambit to extend patent protection on a key Allergan eye product, and last year, when a strategic review didn’t change much at the company.
Allergan’s market cap: $48 billion
GlaxoSmithKline CEO Emma Walmsley $7,662,210
Reuters via handout
Emma Walmsley has led the British drug giant GlaxoSmithKline for about two years, overseeing a time of transition for the company.
Like many of its pharmaceutical rivals, Glaxo is on the hunt for profitable new products that can sustain it for years to come.
Walmsley, who last year was one of just 25 female CEOs in the Fortune 500, comes to the world of healthcare by way of Glaxo’s consumer’s health business. Before joining the drugmaker in 2010, the Oxford University-educated Walmsley worked at L’Oreal, the world’s largest cosmetics company, for nearly 20 years.
But Glaxo is increasingly plotting its way out of consumer health, including its iconic products like Tums and Excedrin, seeing those as incompatible with innovative new products, including in cancer. Late last year, for example, the company announced a $5 billion bet on the cancer drugmaker Tesaro.
GSK’s market cap: $203 billion
Illumina CEO Francis deSouza, $11,067,566
Courtesy Businesswire
Francis deSouza became CEO of Illumina in 2016, succeeding Jay Flatley who had been in the post since 1999.
Illumina makes gene-sequencing technology used to turn samples of DNA into useful data for researchers and genetic testing companies alike.
Illumina’s market cap: $47 billion
See the rest of the story at Business Insider
See Also:
- We got a look at the pitch decks that buzzy $40 million startup HealthJoy used to snag early investors and then execute a huge strategic shift
- A healthcare VC who helps oversee $1.1 billion reveals the biggest mistake she made and how it shapes her investments today
- Meet the woman overseeing a key piece of CVS Health’s plan to change how Americans get healthcare
Source: Business Insider – ecourt@businessinsider.com (Emma Court)